Pottegård, Anton

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., et al. (2021) · BMJ

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 401

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial

Ravn-Nielsen, L. V., Duckert, M.-L., Lund, M. L., Henriksen, J. P., Nielsen, M. L., Eriksen, C. S., Buck, T. C., Pottegård, A., Hansen, M. R., & Hallas, J. (2018) · JAMA Internal Medicine

Pharmaceutical Practices and Patient OutcomesPharmacy and Medical Practices

Cited by 310

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies

Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 207

Association of antithrombotic drug use with subdural hematoma risk

Gaist, D., García Rodríguez, L. A., Hellfritzsch, M., Poulsen, F. R., Halle, B., Hallas, J., & Pottegård, A. (2017) · JAMA

Neurosurgical Procedures and ComplicationsSpinal Hematomas and Complications

Cited by 203

Acetaminophen for Chronic Pain: A Systematic Review on Efficacy

Ennis, Z. N., Dideriksen, D., Vægter, H. B., Handberg, G., & Pottegård, A. (2016) · Basic & Clinical Pharmacology & Toxicology

Musculoskeletal pain and rehabilitationPain Management and Opioid Use

Cited by 129

Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study

Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDrug-Induced Ocular Toxicity

Cited by 85

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease

Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021) · JAMA Neurology

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 84

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study

Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid®

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 81

Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss

Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R. (2024) · Clinical Epidemiology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 60

Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study

Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 46

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects

Sørensen, M. S., Pottegård, A., Andersen, N. E., Thomsen, R. W., & Lundby, C. (2025) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 18

Discontinuation of Semaglutide Therapy for Obesity Management

Mailhac, A., Pedersen, L., Petersen, I., Pottegård, A., Sørensen, H. T., & Thomsen, R. W. (2026) · JAMA Network Open

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1